Novavax (NVAX) Liabilities from Discontinued Operations (2025)
Novavax's (NVAX) quarterly Liabilities from Discontinued Operations came in at 47869000.0 in Q4 2025, down 6.93% quarter-over-quarter from 51435000.0 in Q3 2025.
Novavax (NVAX) Liabilities from Discontinued Operations (2025) Analysis & Trends
Novavax's Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 47869000.0 for Q4 2025.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 47869000.0 in Q4 2025; TTM through Dec 2025 was 47869000.0, a N/A change from a year earlier, with the FY2025 full-year figure at 47869000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations slipped to 47869000.0 in Q4 2025 per NVAX's latest filing, from 51435000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 51435000.0 in Q3 2025 and bottomed at 47869000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 47.87 Mn |
| Dec 31, 2025 | 47.87 Mn |
| Sep 30, 2025 | 51.44 Mn |
| Sep 30, 2025 | 51.44 Mn |